These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 6362851

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. dATP-mediated inhibition of DNA ligase by 2'-deoxycoformycin in T and B cell leukemia.
    Lamballe F, Le Prise PY, Le Gall E, David JC.
    Leukemia; 1989 Feb; 3(2):97-103. PubMed ID: 2783473
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Human B lymphocytes and thymocytes but not peripheral blood mononuclear cells accumulate high dATP levels in conditions simulating ADA deficiency.
    Goday A, Simmonds HA, Morris GS, Fairbanks LD.
    Biochem Pharmacol; 1985 Oct 01; 34(19):3561-9. PubMed ID: 3876835
    [Abstract] [Full Text] [Related]

  • 26. Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro--lack of correlation with clinical response.
    Ho AD, Ganeshaguru K, Knauf W, Dietz G, Trede I, Hoffbrand AV, Hunstein W.
    Leuk Res; 1989 Oct 01; 13(4):269-78. PubMed ID: 2785618
    [Abstract] [Full Text] [Related]

  • 27. Inhibitor of 2',5'-oligoadenylate synthetase induced in human T lymphoblastoid cell line treated with deoxyadenosine, deoxycoformycin and interferon.
    Heike T, Katamura K, Kubota M, Shinomiya K, Mikawa H.
    Biochem Biophys Res Commun; 1985 Mar 29; 127(3):1019-25. PubMed ID: 3872657
    [Abstract] [Full Text] [Related]

  • 28. The biochemical and clinical consequences of 2'-deoxycoformycin in T cell chronic lymphocytic leukaemia.
    Hallam LJ, Van der Weyden MB, Ackland SP, Bagnara AS, Whiteside MG.
    Scand J Haematol; 1984 Jan 29; 32(1):55-64. PubMed ID: 6607510
    [Abstract] [Full Text] [Related]

  • 29. Adenosine and deoxyadenosine toxicity in colony assay systems for human T-lymphocytes, B-lymphocytes, and granulocytes.
    Brox LW, Pollock E, Belch A.
    Cancer Chemother Pharmacol; 1982 Jan 29; 9(1):49-52. PubMed ID: 6982786
    [Abstract] [Full Text] [Related]

  • 30. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
    Venner PM, Glazer RI, Blatt J, Sallan S, Rivera G, Holcenberg JS, Lipton J, Murphy SB, Poplack DG.
    Cancer Res; 1981 Nov 29; 41(11 Pt 1):4508-11. PubMed ID: 6975654
    [Abstract] [Full Text] [Related]

  • 31. B cells as well as T cells form deoxynucleotides from either deoxyadenosine or deoxyguanosine.
    Goday A, Simmonds HA, Morris GS, Fairbanks LD.
    Clin Exp Immunol; 1984 Apr 29; 56(1):39-48. PubMed ID: 6424986
    [Abstract] [Full Text] [Related]

  • 32. 2,6-Diaminopurinedeoxyriboside as a prodrug of deoxyguanosine in L1210 cells.
    Weckbecker G, Cory JG.
    Cancer Res; 1987 May 01; 47(9):2218-23. PubMed ID: 3552212
    [Abstract] [Full Text] [Related]

  • 33. DNA repair in nondividing human lymphocytes: inhibition by deoxyadenosine.
    Cohen A, Thompson E.
    Cancer Res; 1986 Apr 01; 46(4 Pt 1):1585-8. PubMed ID: 3485013
    [Abstract] [Full Text] [Related]

  • 34. Biochemical consequences of 2'-deoxycoformycin treatment in a patient with T-cell lymphoma. Some unusual findings.
    de Korte D, Haverkort WA, van Leeuwen EF, Roos D, van Gennip AH.
    Cancer; 1987 Aug 15; 60(4):750-5. PubMed ID: 3496148
    [Abstract] [Full Text] [Related]

  • 35. Biochemical mechanisms of deoxycoformycin toxicity in chronic leukemias.
    Ganeshaguru K, Ho AD, Piga A, Catovsky D, Hoffbrand AV.
    Leuk Res; 1987 Aug 15; 11(10):941-5. PubMed ID: 3500370
    [Abstract] [Full Text] [Related]

  • 36. Antineoplastic effect of the combination of 2,3-dihydro-1H-pyrazole[2,3a]imidazole plus deoxyadenosine/erythro-9-(2-hydroxyl-3-nonyl)adenine in mice with L1210 leukemia cells.
    Matsumoto M, Weckbecker G, Cory JG.
    Cancer Commun; 1990 Aug 15; 2(1):1-6. PubMed ID: 2369548
    [Abstract] [Full Text] [Related]

  • 37. Alterations in erythrocyte adenine nucleotide pools resulting from 2'-deoxycoformycin therapy.
    Koller CA, Mitchell BS.
    Cancer Res; 1983 Mar 15; 43(3):1409-14. PubMed ID: 6600652
    [Abstract] [Full Text] [Related]

  • 38. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
    Bontemps F, Van den Berghe G.
    Cancer Res; 1989 Sep 15; 49(18):4983-9. PubMed ID: 2788493
    [Abstract] [Full Text] [Related]

  • 39. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
    Lee N, Russell N, Ganeshaguru K, Jackson BF, Piga A, Prentice HG, Foa R, Hoffbrand AV.
    Br J Haematol; 1984 Jan 15; 56(1):107-19. PubMed ID: 6231047
    [Abstract] [Full Text] [Related]

  • 40. The treatment of hairy cell leukemia (HCL) with pentostatin (2'-deoxycoformycin, dCF).
    Spiers AS, Parekh SJ.
    Bone Marrow Transplant; 1989 Jan 15; 4 Suppl 1():173-5. PubMed ID: 2653498
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.